Pharmacophore refinement guides the design of nanomolar-range botulinum neurotoxin serotype a light chain inhibitors

ACS Medicinal Chemistry Letters

Volumn 1, Issue 7, 2010, Pages 301-305

  Nuss, Jonathan E ^a   Dong, Yuxiang ^b   Wanner, Laura M ^a   Ruthel, Gordon ^a   Wipf, Peter ^c   Gussio, Rick ^d   Vennerstrom, Jonathan L ^b   Bavari, Sina ^a   Burnett, James C ^e  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

biothreat agent; Botulinum neurotoxin; gas phase pharmacophore; rational design; small molecule inhibitor

Indexed keywords

2 [4 (4 AMIDINEPHENOXY)PHENYL]INDOLE 6 AMIDINE; ANTITOXIN; BIS [3 AMIDE 5 (IMIDAZOLINO)PHENYL]TEREPHTHALAMIDE; BOTULINUM TOXIN A; SMALL MOLECULE(NONPEPTIDIC)INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; LIGHT CHAIN; PHARMACOPHORE; PRIORITY JOURNAL;

EID: 77958085443     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100056v     Document Type: Article

References (22)

1. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K. D. The Strange Case of the Botulinum Neurotoxin: Using Chemistry and Biology to Modulate the Most Deadly Poison Angew. Chem., Int. Ed. Engl. 2008, 47, 8360-8379
2. http://emergency.cdc.gov/agent/agentlist-category.asp.
3. Foran, P. G.; Davletov, B.; Meunier, F. A. Getting Muscles Moving Again After Botulinum Toxin: Novel Therapeutic Challenges Trends Mol. Med. 2003, 9, 291-299
4. Foran, P. G.; Mohammed, N.; Lisk, G. O.; Nagwaney, S.; Lawrence, G. W.; Johnson, E.; Smith, L.; Aoki, K. R.; Dolly, J. O. Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A. Basis for Distinct Durations of Inhibition of Exocytosis in Central Neurons J. Biol. Chem. 2003, 278, 1363-1371
5. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management J. Am. Med. Assoc. 2001, 285, 1059-1070 (Pubitemid 32176420)
6. Smith, T. J.; Lou, J.; Geren, I. N.; Forsyth, C. M.; Tsai, R.; Laporte, S. L.; Tepp, W. H.; Bradshaw, M.; Johnson, E. A.; Smith, L. A.; Marks, J. D. Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization Infect. Immun. 2005, 73, 5450-5457
7. Wein, L. M.; Liu, Y. Analyzing a Bioterror Attack on the Food Supply: The Case of Botulinum Toxin in Milk Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9984-9989
8. Cai, S.; Singh, B. R. Strategies to Design Inhibitors of Clostridium Botulinum Neurotoxins Infect. Disord.: Drug Targets 2007, 7, 47-57
9. Capkova, K.; Salzameda, N. T.; Janda, K. D. Investigations into Small Molecule Non-Peptidic Inhibitors of the Botulinum Neurotoxins Toxicon 2009, 54, 575-582
10. Burnett, J. C.; Ruthel, G.; Stegmann, C. M.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Stafford, R. G.; Lane, D. J.; Kenny, T. A.; McGrath, C. F.; Wipf, P.; Stahl, A. M.; Schmidt, J. J.; Gussio, R.; Brunger, A. T.; Bavari, S. Inhibition of Metalloprotease Botulinum Serotype A: From a Pseudo-Peptide Binding Mode to a Small Molecule that is Active in Primary Neurons J. Biol. Chem. 2007, 282, 5004-5014
11. Burnett, J. C.; Wang, C.; Nuss, J. E.; Nguyen, T. L.; Hermone, A. R.; Schmidt, J. J.; Gussio, R.; Wipf, P.; Bavari, S. Pharmacophore-Guided Lead Optimization: the Rational Design of a Non-Zinc Coordinating, Sub-Micromolar Inhibitor of the Botulinum Neurotoxin Serotype a Metalloprotease Bioorg. Med. Chem. Lett. 2009, 19, 5811-5813
12. Hermone, A. R.; Burnett, J. C.; Nuss, J. E.; Tressler, L. E.; Nguyen, T. L.; Solaja, B. A.; Vennerstrom, J. L.; Schmidt, J. J.; Wipf, P.; Bavari, S.; Gussio, R. Three-Dimensional Database Mining Identifies a Unique Chemotype that Unites Structurally Diverse Botulinum Neurotoxin Serotype A Inhibitors in a Three-Zone Pharmacophore ChemMedChem 2008, 3, 1905-1912
13. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Solaja, B. A.; Bavari, S. A Refined Pharmacophore Identifies Potent 4-Amino-7-Chloroquinoline-Based Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease J. Med. Chem. 2007, 50, 2127-2136
14. Sellarajah, S.; Lekishvili, T.; Bowring, C.; Thompsett, A. R.; Rudyk, H.; Birkett, C. R.; Brown, D. R.; Gilbert, I. H. Synthesis of Analogues of Congo Red and Evaluation of Their Anti-Prion Activity J. Med. Chem. 2004, 47, 5515-5534
15. Natarajan, J. K.; Alumasa, J. N.; Yearick, K.; Ekoue-Kovi, K. A.; Casabianca, L. B.; de Dios, A. C.; Wolf, C.; Roepe, P. D. 4-N-, 4-S-, and 4-O-Chloroquine Analogues: Influence of Side Chain Length and Quinolyl Nitrogen pKa on Activity Versus Chloroquine Resistant Malaria J. Med. Chem. 2008, 51, 3466-3479
16. Sun, M.; Wei, H.-T.; Li, D.; Zheng, Y.-G.; Cai, J.; Ji, M. Mild and Efficient One-Pot Synthesis of 2-Imidazolines from Nitriles Using Sodium Hydrosulfide as Catalyst Synth. Commun. 2008, 38, 3151-3158
17. Schmidt, J. J.; Bostian, K. A. Endoproteinase Activity of Type A Botulinum Neurotoxin: Substrate Requirements and Activation by Serum Albumin J. Protein Chem. 1997, 16, 19-26
18. Schmidt, J. J.; Bostian, K. A. Proteolysis of Synthetic Peptides by Type A Botulinum Neurotoxin J. Protein Chem. 1995, 14, 703-708
19. Schmidt, J. J.; Stafford, R. G. Fluorigenic Substrates for the Protease Activities of Botulinum Neurotoxins, Serotypes A, B, and F Appl. Environ. Microbiol. 2003, 69, 297-303
20. Schmidt, J. J.; Stafford, R. G. A High-Affinity Competitive Inhibitor of Type A Botulinum Neurotoxin Protease Activity FEBS Lett. 2002, 532, 423-426
21. Schmidt, J. J.; Stafford, R. G.; Bostian, K. A. Type A Botulinum Neurotoxin Proteolytic Activity: Development of Competitive Inhibitors and Implications for Substrate Specificity at the S1' Binding Subsite FEBS Lett. 1998, 435, 61-64
22. Schmidt, J. J.; Stafford, R. G.; Millard, C. B. High-Throughput Assays for Botulinum Neurotoxin Proteolytic Activity: Serotypes A, B, D, and F Anal. Biochem. 2001, 296, 130-137